Tag: Prescription Drugs
Antipsychotics Up Risk for Unexpected Death in Youths
Risk for unexpected deaths increased in higher-dose antipsychotic group versus control group
Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes
Meds Taken Do Not Vary With ADL Impairment in Heart Failure
Adults with heart failure with impairment in activities of daily living take as many meds as those without
SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz
More second primary cancers and more frequent menopausal symptoms seen in tamoxifen vs. placebo arm
SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug
Alemtuzumab label will be updated to include the risk for stroke and arterial dissection
ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL
Improved progression-free survival with ibrutinib for older adults with untreated CLL
Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Lanadelumab Reduces Attack Rate in Hereditary Angioedema
Significant reduction in attack rate compared with placebo seen for three dose regimens of lanadelumab